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Abstract
Using an established international renal cell carcinoma (RCC) database, we retrospectively
characterized the use and efficacy of mammalian target of rapamycin (mTOR) inhibitors in
treatment-naive metastatic RCC (mRCC) patients. Front-line mTOR inhibitors are used in clinical
practice mostly in select patients, who have non-clear cell histology, poor prognostic features, or
as part of clinical trials.
Introduction/Background—Approval of the mTOR inhibitors for the treatment of mRCC was
based on efficacy in poor-risk patients in the first-line setting for temsirolimus and in vascular
endothelial growth factor inhibitor-refractory patients for everolimus. We strove to characterize
temsirolimus and everolimus use and effectiveness in the first-line setting.
Patients and Methods—We performed a retrospective database analysis of mRCC patients
who received mTOR inhibitors as first-line targeted therapy. The Kaplan-Meier product-limit
method was used to estimate the distribution of progression-free survival (PFS) and overall
survival (OS).
Results—We identified 127 mRCC patients who had received a first-line mTOR inhibitor.
Temsirolimus was administered in 93 patients (73%) and everolimus in 34 patients (27%). The
main reasons for choice of temsirolimus were poor-risk disease (38%), non-clear cell histology
(27%), and clinical trial availability (15%), whereas clinical trial (82%) and non-clear cell
histology (6%) drove everolimus selection. Of the temsirolimus and everolimus patients, 58% and
32% were poor-risk according to the International mRCC Database Consortium criteria,
respectively. The median PFS and OS were 3.4 and 12.5 months and 4.8 and 15.9 months with
temsirolimus and everolimus, respectively. Although limited by small numbers, this study
characterizes a real-world, international experience with the use of mTOR inhibition in treatment-
naive mRCC patients.
Conclusion—Poor-risk RCC, non-clear cell histology, and clinical trials were the predominant
reasons for mTOR inhibitor selection in the front-line setting. Because of the different patient
populations in which they were administered, direct comparisons of the front-line efficacy of
temsirolimus and everolimus cannot be made.
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Introduction
Two major classes of targeted therapies, the vascular endothelial growth factor (VEGF)
inhibitors and the mammalian target of rapamycin (mTOR) inhibitors, have been developed
for the treatment of metastatic renal cell carcinoma (mRCC). By inhibiting angiogenesis and
growth factor pathways critical to the growth of mRCC, these agents elicit significant
improvements in progression-free survival (PFS), in objective responses, and in some cases,
overall survival.1–12
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Mammalian target of rapamycin is integral to the regulation of cell growth, proliferation,
metabolism, and autophagy.13 Two mTOR inhibitors are approved to treat advanced renal
cell carcinoma (RCC): temsirolimus and everolimus. Through an allosteric interaction, these
rapalogs complex with an intracellular protein, FK 506 binding protein-12, bind to mTOR,
and competitively inhibit its signaling.14 Because of its role in the regulation of
hypoxiainducible factor (HIF), mTOR blockade also inhibits angiogenesis and other key
HIF genes critical to tumorigenesis and survival.15
With their similar mechanisms of action, temsirolimus and everolimus are often assumed to
have equivalent efficacy. However, they were prospectively studied in very different patient
populations.3,4 Temsirolimus is approved for use in treatment-naive patients based on level
1 evidence that it increases overall survival in poor-risk disease. However, it is important to
remember that it has not been directly compared with a VEGF-targeted therapy in that
setting. Everolimus is a standard therapy in the second-line setting based on its ability to
stabilize disease and prolong PFS in VEGF inhibitor-refractory patients. To enhance our
knowledge of their efficacy and to understand the reasons they are chosen over VEGF
inhibitors, we interrogated the International Metastatic Renal Cell Carcinoma Database
Consortium (IMDC) databank and the longitudinal medical records of our institutions for
the outcomes of patients who received mTOR inhibitors as first-line targeted therapy in a
real-world, unselected setting.
Patients and Methods
Patient Population
The IMDC is a group of academic institutions from Canada, the United States, Singapore,
Denmark, and South Korea. Patient inclusion into the database requires advanced or
metastatic RCC of any histology and treatment with a targeted therapy. For the current
study, 14 centers had data on RCC patients who had received firstline mTOR inhibitors.
Patients were excluded if they received a concurrent VEGF-targeted therapy.
We queried the database for baseline demographic, clinical, laboratory, and outcomes
information. Investigators retrospectively reviewed clinic notes to assess the reason behind
the choice of an mTOR inhibitor. Reasons included IMDC16 or Memorial Sloan-Kettering
Cancer Center (MSKCC)17 poor-risk status, non-clear cell histology or sarcomatoid
features, clinical trial, comorbidity or toxicity concerns with administration of a VEGF
inhibitor, physician choice, insurance issues, history of renal transplant (with the rationale
that rapamycin would be effective at preventing rejection too), and unknown. Survival data
were retrieved from the patient’s medical record or publically available records. Institutional
review board approval was secured from each center.
Statistical Analysis
Summary descriptive statistics were created for baseline characteristics. The Kaplan-Meier
product limit method was used to estimate the distributions of PFS and overall survival for
all patients, and stratified by prognostic groups defined at therapy initiation or by other
covariates of interest. Comparisons between groups were conducted using the log rank test.
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PFS was defined as time from drug initiation to progression, cessation of therapy, death, or
censored at last follow-up. Overall survival was defined as time from drug initiation to death
or censored at last follow-up. Statistical analyses were performed using SAS 9.2 (SAS
Institute, Cary, NC). The cutoff date for data analysis was February 4, 2013.
Results
From July 2004 to January 2013, 127 patients received a first-line mTOR inhibitor for
metastatic RCC. Median follow-up was 22.1 months. Temsirolimus was administered in
most cases and 34 patients received everolimus. Baseline demographic characteristics are
shown in Table 1. Median age in both cohorts was 61 to 62 years. Median Karnofsky
performance status was slightly lower in the temsirolimus group at 80% compared with 90%
in the everolimus group. Approximately half of the patients in each group had clear cell
disease with 40% to 41% of the patients having non-clear cell disease. Sarcomatoid features
were present in 14% of the temsirolimus patients and in 26% of the everolimus patients.
Temsirolimus patients had a lower incidence of previous nephrectomy (62% vs. 82%) and a
greater number of metastatic sites (> 1 site: 84% vs. 76%) compared with the everolimus
cohort. Of the temsirolimus and everolimus patients, 58% and 32% were poor risk according
to IMDC criteria, 27% and 29% were intermediate risk, and 6% and 15% were favorable
risk, respectively.
Retrospective review of clinic notes revealed the reasons behind the choice of an mTOR
inhibitor. Reasons identified included IMDC or MSKCC poor-risk status, non-clear cell
histology or sarcomatoid features, clinical trial, comorbidity or toxicity concerns prohibiting
administration of a VEGF inhibitor, physician choice, insurance issues, history of renal
transplant (with the justification that rapamycin would also be effective at preventing
rejection too), and unknown. Poor risk status (38%), non-clear cell histology (27%), and
clinical trial (15%) motivated physicians to select temsirolimus and clinical trial (82%) and
non-clear cell histology (6%) drove choice of everolimus (Table 2).
The median PFS in all patients was 3.4 months (n = 90) for temsirolimus and 4.8 (n = 32)
months for everolimus (Table 3). There were no significant differences in efficacy between
the clear cell and non-clear cell subsets (Kaplan-Meier curves not shown). In clear cell
disease, temsirolimus induced a median PFS of 3.3 months (n = 47) and 4.8 months (n = 36)
in non-clear cell disease (P = .61). Median PFS was 5.5 months (n = 17) for clear cell
disease and 3.3 months (n = 14) for non-clear cell disease when treated with everolimus (P
= .6). Temsirolimus elicited a median PFS of 8.3 (n = 6), 5.3 (n = 25), and 3.1 (n = 40)
months in good-, intermediate-, and poor-risk patients, respectively. Everolimus
administration resulted in a median PFS of 11.3 (n = 5), 2.3 (n = 10), and 5.3 (n = 7) months
in good-, intermediate-, and poor-risk patients.
Median overall survival was 12.5 and 15.9 months for temsirolimus and everolimus,
respectively (Table 3). Non-clear cell disease patients lived a median of 14.3 months if they
received temsirolimus (n = 36) compared with 12.5 months (n = 49) if they had clear cell
disease (P = .81). Everolimus induced a median overall survival of 20.6 months (n = 14) in
non-clear cell disease and clear cell patients attained a median overall survival of 17.2
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months (n = 19). Median overall survival for good-, intermediate-, and poor-risk patients
who received temsirolimus was 16.2 (n = 6), 14.5 (n = 25), and 5.3 (n = 42) months,
respectively. For the everolimus cohort, median overall survival was 16.2 (n = 5), 15.9 (n =
10), and 19.4 (n = 7) months for the good-, intermediate-, and poor-risk patients.
In the 97 patients with response data, partial responses were achieved in 5% and 8% of
temsirolimus and everolimus patients, respectively. Most patients experienced disease
stabilization as best response (53% for temsirolimus; 58% for everolimus) for an overall
clinical benefit of 58% with temsirolimus and 66% for everolimus. Primary refractory
disease with progressive disease as best response occurred in 41% of temsirolimus patients
and 33% of everolimus patients.
At the time of the analysis, 52 patients (41%) had received a second-line therapy; 44% of
everolimus and 40% of temsirolimus patients. VEGF inhibitors were chosen in most cases
(92%).
Discussion
The mTOR inhibitors are a distinct class of targeted therapies approved for the treatment of
advanced RCC. Although they can provide clinical benefit in the form of stabilizing disease
and prolonging time to disease progression, outstanding questions persist with respect to the
optimal timing, sequencing, and patient population in which to use these agents. We
undertook the current study to assess the practice patterns and efficacy of first-line mTOR
inhibition in an unselected, real-world population of patients with metastatic RCC of any
histology.
In our study, reasons for choosing an mTOR inhibitor over a VEGF targeted therapy were
consistent with their approved indications and current thinking on their most appropriate use
at the time of the selection. The lower utilization of everolimus reflects that it was not
approved in the first-line setting and thus. it was not surprising that clinical trial was the
most common reason for its upfront use (82%). In the case of temsirolimus, the most
common reasons for administration were poor-risk disease (38%) followed by non-clear cell
histology (27%) and clinical trial availability (15%). Comorbidities and preferable toxicity
profile were additional justifications for choosing an mTOR inhibitor over a VEGF targeted
agent. These latter results likely highlight physician knowledge of the well characterized
VEGF inhibitor cardiovascular toxicities and concerns for the potential to exacerbate
preexisting refractory hypertension or clinically significant congestive heart failure as
motivating factors for the choice of mTOR inhibition over VEGF blockade in some
cases.18,19
To provide a historical perspective in which to frame our results, in the global phase III
registration study, temsirolimus achieved a median PFS of 3.7 months and overall survival
of 10.9 months in previously untreated patients with extensive disease and multiple poor
prognostic risk features such as absence of nephrectomy, anemia, increased calcium levels,
increased lactate dehydrogenase, poor performance status, and multiple sites of metastases.3
In our unselected patient population, median PFS was 3.4 months in the entire cohort and
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3.1 months in the poor-risk patients with median overall survivals of 12.5 months and 5.3
months, respectively. In a recently published prospective observation trial of temsirolimus
use in Germany, 42% of patients received the drug in the first-line setting.20 In the
treatment-naive patients, median PFS and overall survival were 5.3 and 10.5 months.
MSKCC risk stratification data were missing in > 100 patients, but in those for whom it was
available, median PFS and overall survival were significantly better in the intermediate risk
patients compared with the poor risk patients at 5.3 versus 2.4 months (P = .001) and 11.6
versus 5.6 months (P < .001), which was consistent with our data. Clear cell or non-clear
cell histology did not affect outcomes in terms of PFS, overall survival, or clinical benefit in
the German study.
In our everolimus cohort, the median PFS was 4.8 months, which is more in line with a
historical second-line VEGF or mTOR inhibitor response.21 This inferior outcome might
reflect the higher percentage of poor risk patients in our cohort (21%) and a lower
percentage of good risk patients (15%). In addition, risk status was unknown in 35% of our
patients making an even higher degree of less favorable disease patients possible. Because
of the retrospective nature of our study, no direct comparisons should be made to the
temsirolimus cohort. However, the slightly better PFS in our everolimus cohort likely
reflects that most of these patients were healthy enough to be deemed eligible for a clinical
trial. Past work by our group using the same IMDC database has shown that mRCC patients
eligible for a clinical trial have significantly better clinical outcomes in terms of objective
responses, PFS, and overall survival compared with patients who would likely be considered
ineligible.22
The most informative trial regarding the effectiveness of everolimus in the front-line setting
is the recently reported randomized phase II study, RECORD-3, which assessed whether
everolimus was noninferior to sunitinib in treatment-naive patients (n = 471).23 RECORD-3
is the first prospective study to provide data on everolimus’ efficacy in treatment-naive and
more favorable risk patients (MSKCC: 29% good, 56% intermediate). Everolimus elicited a
median PFS of 7.9 months but did not achieve ‘noninferiority’ against sunitinib (10.7
months). Focusing on patients with good-risk disease, the median PFS of 11.3 months
elicited by everolimus in our study was in line with that seen in the RECORD-3 good-risk
everolimus cohort (11.1 months). In our study and RECORD-3, everolimus’ effect in
treatment-naive patients with poor-risk disease was dismal. Further, the RECORD-3 trial
emphasized that these poor risk patients have bleak outcomes regardless of the type of
therapy administered (median PFS: 2.6 vs. 3.0 months with everolimus and sunitinib,
respectively), underscoring the critical need for novel agents or therapeutic strategies in this
patient population.
Because of reports of upregulation of the mTOR pathway in non-clear cell disease, the
question has loomed as to whether mTOR inhibitors should be the preferred first-line
selection for the non-clear cell histologies in the absence of a definitive clinical trial.3 In the
phase 3 registration trial for temsirolimus, approximately 20% of patients had non-clear cell
disease, most of which were the papillary subtype. PFS ranged from 5.9 months for papillary
disease to 7 months for all non-clear cell histologies to 5.5 months for the clear cell subset.24
In a single-arm phase II study of 49 patients with non-clear cell RCC, everolimus elicited
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objective responses in 10%, disease stabilization in 51%, and a median PFS of 5.2 months.25
Previous VEGF blockade did not decrease the efficacy of everolimus compared with
patients who were treatment-naive. In our study, each cohort was comprised of
approximately 40% of patients with non-clear cell disease. Temsirolimus induced a median
PFS of 4.8 months and everolimus a median of 5.5 months. Comparatively, in prospective
single arm studies and the Expanded Access Program, sunitinib achieved objective response
rates of 5% to 36%, median PFS ranging from 2.7 to 7.8 months, and median overall
survival of 13.4 to 25.6 months in non-clear cell disease.26–28 In the RECORD-3 trial,
subset analysis of very small cohorts showed that everolimus did not outperform sunitinib in
non-clear cell disease (median PFS, 5.1 months; n = 24/31 vs. 7.2 months; n = 23/35).
Ultimately, 2 prospective trials powered to compare the efficacy of everolimus with
sunitinib in mRCC patients with non-clear cell histology will shed additional light on this
issue (NCT01108445, NCT01185366).
Finally, the question remains as to whether these agents, which are assumed to have very
similar mechanisms of action, are indeed equivalently therapeutic. In our study, because of
the different populations in which they were administered, we cannot make direct
comparisons of the front-line efficacy of temsirolimus compared with everolimus. Most
temsirolimus patients were poorrisk, which their dismal PFS and survival reflect, and the
better outcomes in the everolimus patients highlight that most were not poor-risk and were
healthy enough to be eligible for clinical trials. In addition to efficacy considerations, ease
and route of administration, availability, and cost, all factor into drug selection.
Temsirolimus’ intravenous formulation ensures compliance and absorption but conversely
requires the significant time commitment of weekly trips to the clinic. Everolimus provides
easy oral administration and less frequent visits but does not always assure compliance, and
its absorption might be compromised by food or gastrointestinal disorders. With respect to
cost and resources, an observational, retrospective study of a large nationwide community
oncology network found everolimus to be more cost-effective and resourcesaving than
temsirolimus.29
The limitations of our study are its retrospective nature and the small numbers of patients
who received mTOR inhibition as their first-line treatment. Because this was not a
prospective study, clinical outcomes data were investigator-assessed and thus, subject to
clinician bias. Nonstandardized scan intervals might have resulted in lead or length time bias
in calculating PFS. Finally, pathology was not centrally reviewed and as such there might be
a degree of variability in histologic classification. However, this work characterizes a real-
world experience of first-line mTOR inhibition in an unselected patient population, which
makes these results potentially more generalizable than results of highly selected clinical
trial populations.
Conclusion
Because of the results of the prospective RECORD-3 trial, upfront VEGF inhibition or
clinical trial is preferred over mTOR blockade in advanced, treatment-naive patients with
clear cell RCC. Temsirolimus can be considered an option for poor prognosis, treatment-
naive patients in the first-line setting, but the disappointing outcomes observed in our
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analysis and in the RECORD-3 trial by either class of agents in poor-risk disease targets this
population as prime for investigation of novel agents.
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Clinical Practice Points
• Temsirolimus and everolimus are mTOR inhibitors approved for the treatment
of advanced RCC. Temsirolimus was approved for use in the first-line setting in
patients with poor-risk features while everolimus was initially evaluated in
patients whose disease had progressed after treatment with a VEGF inhibitor.
• We examined the reasons for choice and the resultant efficacy of front-line
mTOR inhibitor administration in our international database consortium.
• In clinical practice, we observed that use of mTOR inhibitors in the first-line
setting tended to be in select patients, who had non-clear cell histology, poor
prognostic features, or as part of clinical trials.
• Temsirolimus can be considered an option for poor prognosis, treatment-naive
patients, but has never been directly compared with a VEGF targeted therapy in
this setting. Because of the results of the prospective RECORD-3 trial, which
did not prove everolimus to be noninferior to sunitinib, VEGF inhibition or
clinical trial is generally preferred over mTOR blockade in advanced treatment-
naive RCC patients.
• The disappointing outcomes observed in our retrospective population-based
analysis and the prospective RECORD-3 trial by either class of agents in poor-
risk disease highlight the need for novel treatment strategies and targets in this
population.
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Table 1
Patient and Tumor Characteristics (n = 127)
Characteristic
Temsirolimus
(n = 93)
Everolimus
(n = 34)
Median Age at Initiation of Therapy, Years 61 62
Median Performance Score (KPS) 80% 90%
Sex
  Male 66 (71) 26 (76)
  Female 27 (29) 8 (24)
Pathology
Clear Cell 48 (52) 17 (50)
Non-Clear Cell 37 (40) 14 (41)
Unknown 8 (9) 3 (9)
Sarcomatoid Features
  Yes 13 (14) 9 (26)
  No 67 (72) 21 (62)
  Unknown 13 (14) 4 (12)
Previous Nephrectomy
  Yes 58 (62) 28 (82)
  No 35 (38) 6 (18)
Number of Metastases >1 78 (84) 26 (76)
Metastatic Site
  Lung 61 (66) 18 (53)
  Lymph node 59 (63) 19 (56)
  Bone 38 (41) 10 (29)
  Liver 26 (28) 8 (24)
  Brain 8 (9) 2 (6)
IMDC Risk Groupa
  Favorable 6 (6) 5 (15)
  Intermediate 25 (27) 10 (29)
  Poor 42 (45) 7 (21)
  Unknown 20 (22) 12 (35)
Data are presented as n (%) except where otherwise noted.
Abbreviations: IMDC = International Metastatic Renal Cell Carcinoma Database Consortium; KPS = Karnofsky performance status.
a
IMDC poor prognosis risk factors include absence of nephrectomy, KPS < 70%, hemoglobin level below normal, high serum corrected calcium,
high absolute neutrophil count, and thrombocytosis.
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Table 2
Reason for mTOR Inhibitor Selection Over VEGF-Targeted Therapy
Reason
Temsirolimus
(n = 93)
Everolimus
(n = 34)
Poor Risk 38% (35) 3% (1)
Non-Clear Cell Histology 27% (25) 6% (2)
Clinical Trial 15% (14) 82% (28)
Comorbidity or Toxicity Concerns 10% (9) 6% (2)
Physician’s Choice 4% (4) 0% (0)
Insurance Issues 3% (3) 0% (0)
Othera 3% (3) 3% (1)
Data are presented as percentage (n).
aOther included: status post renal transplant (n = 2), sarcomatoid histology (n = 1), unknown (n = 1).
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